Spots Global Cancer Trial Database for Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer
Official Title: A Phase II Study of Single-agent Regorafenib in the First Line Treatment of Frail and/or Unfit for Polychemotherapy Patients With Metastatic Colorectal Cancer (mCRC)
Study ID: NCT01875380
Interventions
Study Description
Brief Summary: The purpose of this study is to assess the efficacy and safety of single-agent regorafenib in the first line treatment of frail and/or unfit for polychemotherapy patients with metastatic colorectal cancer (mCRC)
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Spanish Cooperative Group for Digestive Tumour Therapy (TTD), Madrid, , Spain
Contact Details
Name: Alfredo Carrato, MD-PhD
Affiliation: Ramon y Cajal University Hospital
Role: STUDY_CHAIR
Name: Enrique Grande, MD
Affiliation: Ramon y Cajal University Hospital
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
